New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareFOXO4-DRI vs Noopept

FOXO4-DRI vs Noopept

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
FOXO4-DRI
Cognitive Enhancement
Noopept
Summary
FOXO4-DRI is a D-retro-inverso peptide derived from the FOXO4 protein that selectively induces apoptosis in senescent cells. By disrupting the FOXO4-p53 interaction that keeps senescent cells alive, it triggers programmed cell death specifically in these aging, pro-inflammatory cells while sparing healthy tissue.
Noopept is a potent dipeptide-derived nootropic from Russia, structurally related to piracetam but estimated to be 1,000 times more potent by mass. It enhances memory consolidation, learning, and recall while providing neuroprotection via BDNF and NGF upregulation.
Half-Life
Estimated 2-4 hours (D-amino acid confers resistance to proteolysis)
~5–10 minutes but metabolite (CPG) effects last hours
Admin Route
Subcutaneous, Intraperitoneal (research)
Oral, Sublingual, Intranasal
Research
Typical Dose
5 mg/kg in rodent studies; human equivalent approximately 0.5-1 mg/kg
10–30 mg
Frequency
3 consecutive days per cycle
1–2x daily
Key Benefits
  • Selectively clears senescent cells (senolytics)
  • Reduces senescence-associated secretory phenotype (SASP) and chronic inflammation
  • Demonstrated restoration of physical fitness in aged mice
  • May improve healthspan and reduce age-related tissue dysfunction
  • Potential for treatment of age-related pathologies driven by cellular senescence
  • Does not affect healthy non-senescent cells at therapeutic doses
  • Enhances memory formation and recall
  • Improves learning speed and cognitive processing
  • Neuroprotective via BDNF/NGF upregulation
  • Anxiolytic at low-to-moderate doses
  • Improves verbal fluency and information processing
  • Antioxidant (reduces oxidative damage in neurons)
  • May improve cognitive symptoms of mild cognitive impairment
Side Effects
  • Limited human data; largely preclinical evidence
  • Possible temporary inflammatory response as senescent cells are cleared (senolytic effect)
  • Weight loss observed at high doses in rodent studies
  • Unknown long-term safety profile in humans
  • Headaches (choline depletion — pair with choline source)
  • Irritability or anxiety at high doses
  • Overstimulation
  • Rare: brain fog with chronic use
  • +1 more
Stacks With